Biogen Inc. spin-off Bioverativ Inc. will pay $400 million up front plus assumed cash to acquire True North Therapeutics Inc., a privately held Ipierian Inc. spinout with an early stage FDA breakthrough-designated candidate for the rare blood disorder cold agglutinin disease (CAD).